July 1, 2024

IceCure’s XSense Cryoablation System With CryoProbes Cleared by FDA

July 1, 2024—IceCure Medical Ltd. announced it has received FDA clearance for its XSense cryoablation system with CryoProbes.

According to the company, the next-generation, single-probe cryoablation system is designed to destroy tissue—including fibroadenomas, kidney tissue, liver metastases, tumors, skin lesions, and warts—by the application of extreme cold temperatures.

IceCure stated that XSense and its cryoprobes are cleared for all the indications for which the company’s ProSense system has already received FDA clearance, including general minimally invasive cryoablation in the fields of general surgery, dermatology, neurology (including cryoanalgesia), thoracic surgery, otorhinolaryngology, gynecology, oncology, proctology, and urology.

Subscribe to our weekly newsletter.

Stay informed on the week's top stories including literature summaries, device approvals, guideline changes, and more. Plus, get our latest issues & supplements delivered to your inbox each month.

July 1, 2024

IceCure’s XSense Cryoablation System With CryoProbes Cleared by FDA

Current Issue

Keep In Touch